5-(Azetidin-3-yloxy)-2-bromopyridine
- $350 - $2027.76
- Product name: 5-(Azetidin-3-yloxy)-2-bromopyridine
- CAS: 1146089-82-8
- MF: C8H9BrN2O
- MW: 229.07
- EINECS:
- MDL Number:MFCD22690537
- Synonyms:5-(Azetidin-3-yloxy)-2-bromopyridine;Pyridine, 5-(3-azetidinyloxy)-2-bromo-
4 prices
Selected condition:
Brand
- Alichem
- Chemenu
- Crysdot
- TRC
Package
- 100mg
- 1g
- 5g
- ManufacturerAlichem
- Product number1146089828
- Product description5-(Azetidin-3-yloxy)-2-bromopyridine
- Packaging5g
- Price$2027.76
- Updated2021-12-16
- Buy
- ManufacturerChemenu
- Product numberCM285605
- Product description5-(Azetidin-3-yloxy)-2-bromopyridine 95+%
- Packaging1g
- Price$443
- Updated2021-12-16
- Buy
- ManufacturerCrysdot
- Product numberCD11346847
- Product description5-(Azetidin-3-yloxy)-2-bromopyridine 97%
- Packaging1g
- Price$469
- Updated2021-12-16
- Buy
- ManufacturerTRC
- Product numberA965518
- Product description5-(Azetidin-3-yloxy)-2-bromopyridine
- Packaging100mg
- Price$350
- Updated2021-12-16
- Buy
Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
---|---|---|---|---|---|---|
Alichem | 1146089828 | 5-(Azetidin-3-yloxy)-2-bromopyridine | 5g | $2027.76 | 2021-12-16 | Buy |
Chemenu | CM285605 | 5-(Azetidin-3-yloxy)-2-bromopyridine 95+% | 1g | $443 | 2021-12-16 | Buy |
Crysdot | CD11346847 | 5-(Azetidin-3-yloxy)-2-bromopyridine 97% | 1g | $469 | 2021-12-16 | Buy |
TRC | A965518 | 5-(Azetidin-3-yloxy)-2-bromopyridine | 100mg | $350 | 2021-12-16 | Buy |
Properties
Boiling point :331.4±42.0 °C(Predicted)
Density :1.569±0.06 g/cm3(Predicted)
storage temp. :2-8°C(protect from light)
pka :8.83±0.40(Predicted)
Density :1.569±0.06 g/cm3(Predicted)
storage temp. :2-8°C(protect from light)
pka :8.83±0.40(Predicted)
Safety Information
Symbol(GHS): | |||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Signal word: | Warning | ||||||||||||||||||||||||||||
Hazard statements: |
|
||||||||||||||||||||||||||||
Precautionary statements: |
|